MARKET

OMER

OMER

Omeros
NASDAQ
3.360
-0.120
-3.45%
After Hours: 3.600 +0.24 +7.14% 19:59 07/18 EDT
OPEN
3.550
PREV CLOSE
3.480
HIGH
3.630
LOW
3.340
VOLUME
681.36K
TURNOVER
--
52 WEEK HIGH
13.60
52 WEEK LOW
2.950
MARKET CAP
196.87M
P/E (TTM)
-1.2725
1D
5D
1M
3M
1Y
5Y
1D
H.C. Wainwright Sticks to Their Buy Rating for Omeros (OMER)
TipRanks · 5d ago
Weekly Report: what happened at OMER last week (0707-0711)?
Weekly Report · 5d ago
Weekly Report: what happened at OMER last week (0630-0704)?
Weekly Report · 07/07 11:56
Weekly Report: what happened at OMER last week (0623-0627)?
Weekly Report · 06/30 12:04
Omeros Is Maintained at Buy by D. Boral Capital
Dow Jones · 06/30 12:03
Omeros submission adds another 2026 catalyst, says H.C. Wainwright
TipRanks · 06/27 13:35
Omeros submits narsoplimab marketing authorization application to the EMA
TipRanks · 06/27 12:50
Omeros Submits MAA To EMA For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Benzinga · 06/27 12:33
More
About OMER
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Webull offers Omeros Corp stock information, including NASDAQ: OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.